Can molecular biomarkers replace a clinical risk score for resectable colorectal liver metastasis?
In resectable colorectal liver metastasis (CRLM) the role and use of molecular biomarkers is still controversial. Several biomarkers have been linked to clinical outcomes in CRLM, but none have so far become routine for clinical decision making. For several reasons, the clinical risk score appears to no longer hold the same predictive value. Some of the reasons include the ever expanding indications for liver resection, which now increasingly tend to involve extrahepatic disease, such as lung metastases (both resectable and non-resectable) and the shift in indication from "what is taken out" (e.g., how much liver has to be resected) to "what is left behind" (that is, how much functional liver tissue the patient has after resection). The latter is amenable to modifications by using adjunct techniques of portal vein embolization and the associating liver partition and portal vein ligation for staged hepatectomy techniques to expand indications for liver resection. Added to this complexity is the increasing number of molecular markers, which appear to hold important prognostic and predictive information, for which some will be discussed here. Beyond characteristics of tissue-based genomic profiles will be liquid biopsies derived from circulating tumor cells and cell-free circulating tumor DNA in the blood. These markers are present in the peripheral circulation in the majority of patients with metastatic cancer disease. Circulating biomarkers may represent more readily available methods to monitor, characterize and predict cancer biology with future implications for cancer care.
Torhild Veen, Kjetil Søreide, Department of Gastrointestinal Surgery, HPB Unit, Stavanger University Hospital, N-4068 Stavanger, Norway.
Torhild
T
Veen
Torhild Veen, Kjetil Søreide, Department of Gastrointestinal Surgery, HPB Unit, Stavanger University Hospital, N-4068 Stavanger, Norway.
Kjetil
K
Søreide
Circulating tumor cell; Colorectal cancer; Disease-free survival; KRAS; Liver metastasis; Liver surgery; Molecular biomarkers; Overall survival